DermaXon announces its partnership with VantAI, a Roivant Biosciences Vant company, for the rapid acceleration of two of its drug development programs. VantAI leads the computational drug discovery space with technology at the bleeding edge of machine learning and deep systems biology. Together, DermaXon and VantAI are pushing the limits of drug design for first-in-class small molecules and rapidly optimizing lead drug candidates for lower toxicity and higher tolerability in patients.